Web1 dag geleden · Price To Free Cash Flow is a widely used stock evaluation measure. Find the latest Price To Free Cash Flow for Ionis Pharmaceuticals (IONS) WebCompany. Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on cardiovascular and neurology franchises. The Company’s products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients with spinal muscular atrophy …
IONS Stock Forecast — Price Target for 2024 — TradingView
WebSee Ionis Pharmaceuticals, Inc. stock price prediction for 1 year made by analysts and compare it to price changes over time to develop a better trading strategy. Web14 aug. 2024 · News Ionis Pharmaceuticals Inc. Significant News Only No significant news for IONS in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.90 … dr heather mcintyre morrisburg
IONS - Ionis Pharmaceuticals Stock Snapshot Chart - Barchart.com
WebIonis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo Finance Personal Finance U.S. markets closed S&P Futures 0.00(0.00%) Dow Futures 33,683.00 … Discover historical prices for IONS stock on Yahoo Finance. View daily, weekly or … Find the latest Ionis Pharmaceuticals, Inc. (IONS) stock discussion in Yahoo … Find out all the key statistics for Ionis Pharmaceuticals, Inc. (IONS), including … See Ionis Pharmaceuticals, Inc. (IONS) stock analyst estimates, including … Get the latest Ionis Pharmaceuticals, Inc. (IONS) stock news and headlines to … See the company profile for Ionis Pharmaceuticals, Inc. (IONS) including … View the basic IONS option chain and compare options of Ionis … Find out the direct holders, institutional holders and mutual fund holders for … WebIONIS PHARMACEUTICALS, INC. (SWX:IONS) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share IONIS PHARMACEUTICALS, INC. Swiss ... WebFind real-time IONS - Ionis Pharmaceuticals Inc stock quotes, company profile, news and forecasts from CNN Business. dr heather merchut